RJA
BMY icon

Ross\Johnson & Associates’s Bristol-Myers Squibb BMY Stock Holding History

Ross\Johnson & Associates’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$576 Buy
10
+8
+400% +$459 0.01% 124
2026
Q1 		$121 Hold
2
– – ﹤0.01% 196
2025
Q4 		$108 Hold
2
– – ﹤0.01% 303
2025
Q3 		$90 Hold
2
– – ﹤0.01% 203
2025
Q2 		$93 Sell
2
-5
-71% -$245 ﹤0.01% 199
2025
Q1 		$426 Buy
+7
New +$408 0.01% 254

Other funds holding BMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Ross\Johnson & Associates's BMY Position: Q2 2026 in Review

Ross\Johnson & Associates increased its Bristol-Myers Squibb (BMY) stake by 400% in Q2 2026, buying an estimated $459 and bringing the position to 10 shares worth $576. The position accounts for 0.01% of the portfolio, ranked #124.

Ross\Johnson & Associates first reported a position in BMY in Q1 2025 and has held it in 6 quarters since. 2,521 funds tracked by Wall St. Rank hold BMY as of Q2 2026.

  • Ross\Johnson & Associates held 10 shares of Bristol-Myers Squibb worth $576 as of Q2 2026.
  • Ross\Johnson & Associates bought 8 Bristol-Myers Squibb shares in Q2 2026, an estimated $459.
  • Bristol-Myers Squibb made up 0.01% of Ross\Johnson & Associates's portfolio in Q2 2026, its #124 holding.
  • Ross\Johnson & Associates first reported a position in Bristol-Myers Squibb in Q1 2025 and has held it in 6 quarters since.
  • 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.

Based on Ross\Johnson & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.